Skip to main content
SpringerLink
Log in

Overview of Metabolic Syndrome

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Metabolic Syndrome

  • 58 Accesses

Abstract

The diagnosis of metabolic syndrome is based on the presence of central (abdominal) obesity, increased blood pressure, elevated glucose and triglycerides, and low high-density lipoprotein cholesterol (HDL-C) levels. The prevalence of metabolic syndrome has increased globally mainly due to excessive intake of energy-dense food and reduced physical activity. Metabolic syndrome increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases, nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, cancer and other diseases. The purpose of this book is to highlight the epidemiology, pathophysiology, clinical features, and treatment of metabolic syndrome. We are hopeful the chapters will provide valuable current insights as well as critical questions to guide future research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.

    Article  CAS  PubMed  Google Scholar 

  2. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366(9491):1059–62. https://doi.org/10.1016/S0140-6736(05)67402-8.

    Article  PubMed  Google Scholar 

  3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–80. https://doi.org/10.1111/j.1464-5491.2006.01858.x.

    Article  CAS  PubMed  Google Scholar 

  4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on E, Prevention, Hational Heart L, Blood I, American Heart A, World Heart F, International Atherosclerosis S, International Association for the Study of O. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world Heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.

    Article  CAS  PubMed  Google Scholar 

  5. Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15(9):668–76.

    Article  CAS  PubMed  Google Scholar 

  6. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, Group C-IS. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–43. https://doi.org/10.1002/oby.20309.

    Article  CAS  PubMed  Google Scholar 

  7. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.

    Article  CAS  PubMed  Google Scholar 

  8. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1.

    Article  CAS  PubMed  Google Scholar 

  9. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of insulin resistance (EGIR). Diabet Med. 1999;16(5):442–3.

    Article  CAS  PubMed  Google Scholar 

  10. Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. (1999). The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65(1):101–2.

    Article  PubMed  Google Scholar 

  11. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart study. N Engl J Med. 1998;338(23):1650–6. https://doi.org/10.1056/NEJM199806043382302.

    Article  CAS  PubMed  Google Scholar 

  12. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11. https://doi.org/10.1016/j.phrs.2014.04.004.

    Article  CAS  PubMed  Google Scholar 

  13. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25–26 August 2002, Washington, DC. Diabetes Care. 2003;26(4):1297–303.

    Article  PubMed  Google Scholar 

  14. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. https://doi.org/10.1210/jc.2011-2260.

    Article  CAS  PubMed  Google Scholar 

  15. Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence. 2012;6:449–55. https://doi.org/10.2147/PPA.S23232.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stansfeld SA, Juneja M, Alberti KG. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia. 1997;40(11):1341–9. https://doi.org/10.1007/s001250050830.

    Article  CAS  PubMed  Google Scholar 

  17. Chien KL, Lee BC, Hsu HC, Lin HJ, Chen MF, Lee YT. Prevalence, agreement and classification of various metabolic syndrome criteria among ethnic Chinese: a report on the hospital-based health diagnosis of the adult population. Atherosclerosis. 2008;196(2):764–71. https://doi.org/10.1016/j.atherosclerosis.2007.01.006.

    Article  CAS  PubMed  Google Scholar 

  18. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. https://doi.org/10.1016/S0140-6736(12)60367-5.

    Article  CAS  Google Scholar 

  19. Chrysant SG, Chrysant GS, Chrysant C, Shiraz M. The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr Clin Pharmacol. 2010;5(2):89–95.

    Article  CAS  PubMed  Google Scholar 

  20. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, Investigators C. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96. https://doi.org/10.1016/S0140-6736(04)16895-5.

    Article  CAS  PubMed  Google Scholar 

  21. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and nutrition examination survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;157(8):821–7. https://doi.org/10.1001/archpedi.157.8.821.

    Article  PubMed  Google Scholar 

  22. Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States adolescents, from the National Health and nutrition examination survey, 1999–2002. J Pediatr. 2008;152(2):165–70. https://doi.org/10.1016/j.jpeds.2007.06.004.

    Article  PubMed  Google Scholar 

  23. Coomans CP, Geerling JJ, van den Berg SA, van Diepen HC, Garcia-Tardon N, Thomas A, Schroder-van der Elst JP, Ouwens DM, Pijl H, Rensen PC, Havekes LM, Guigas B, Romijn JA. The insulin sensitizing effect of topiramate involves KATP channel activation in the central nervous system. Br J Pharmacol. 2013;170(4):908–18. https://doi.org/10.1111/bph.12338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab. 2004;89(1):108–13. https://doi.org/10.1210/jc.2003-031188.

    Article  CAS  PubMed  Google Scholar 

  25. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4–7.

    Article  CAS  PubMed  Google Scholar 

  26. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the third National Health and nutrition examination survey. Circulation. 2004;110(16):2494–7. https://doi.org/10.1161/01.CIR.0000145117.40114.C7.

    Article  PubMed  Google Scholar 

  27. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.

    Article  CAS  PubMed  Google Scholar 

  28. Echouffo-Tcheugui JB, et al. Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the Framingham Heart study. J Clin Endocrinol Metab. 2019;104(3):738–52.

    Article  PubMed  Google Scholar 

  29. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult Treatment panel III). JAMA. 2001;285(19):2486–97.

    Article  Google Scholar 

  30. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102(1):42–7.

    Article  CAS  PubMed  Google Scholar 

  31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and nutrition examination survey. JAMA. 2002;287(3):356–9.

    Article  PubMed  Google Scholar 

  32. Frigolet ME, Torres N, Tovar AR. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem. 2013;24(12):2003–15. https://doi.org/10.1016/j.jnutbio.2013.07.002.

    Article  CAS  PubMed  Google Scholar 

  33. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9. https://doi.org/10.1016/j.amjmed.2006.02.031.

    Article  CAS  PubMed  Google Scholar 

  34. Gill H, Mugo M, Whaley-Connell A, Stump C, Sowers JR. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci. 2005;330(6):290–4.

    Article  PubMed  Google Scholar 

  35. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart A, National Heart L, Blood I. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8. https://doi.org/10.1161/01.CIR.0000111245.75752.C6.

    Article  PubMed  Google Scholar 

  36. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart A, National Heart L, Blood I. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404.

    Article  PubMed  Google Scholar 

  37. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41(6):715–22.

    Article  CAS  PubMed  Google Scholar 

  38. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care. 2002;25(11):2016–21.

    Article  CAS  PubMed  Google Scholar 

  39. Harzallah F, Alberti H, Ben Khalifa F. The metabolic syndrome in an Arab population: a first look at the new international diabetes federation criteria. Diabet Med. 2006;23(4):441–4. https://doi.org/10.1111/j.1464-5491.2006.01866.x.

    Article  CAS  PubMed  Google Scholar 

  40. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study G. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the diabetes prevention study cohort. Diabetes Care. 2004;27(9):2135–40.

    Article  PubMed  Google Scholar 

  41. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989;83(4):1168–73. https://doi.org/10.1172/JCI113997.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112–9. https://doi.org/10.1016/j.jacc.2007.01.088.

    Article  CAS  PubMed  Google Scholar 

  43. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K, Greenland Population S. Prevalence of the metabolic syndrome among the Inuit in Greenland. A comparison between two proposed definitions. Diabet Med. 2004;21(11):1237–42. https://doi.org/10.1111/j.1464-5491.2004.01294.x.

    Article  CAS  PubMed  Google Scholar 

  44. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes A, European Association for the Study of D. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2005;28(9):2289–304.

    Article  PubMed  Google Scholar 

  45. Koo BK. Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes Metab J. 2014;38(1):32–4. https://doi.org/10.4093/dmj.2014.38.1.32.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47(8):1403–10. https://doi.org/10.1007/s00125-004-1472-x.

    Article  CAS  PubMed  Google Scholar 

  47. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart study. JAMA. 2003;290(17):2271–6. https://doi.org/10.1001/jama.290.17.2271.

    Article  CAS  PubMed  Google Scholar 

  48. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014;34(9):1820–6. https://doi.org/10.1161/ATVBAHA.114.303035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Cho SI, Park KS, Lee HK, Jang HC, Koh KK. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and nutrition examination survey for 1998–2007. Diabetes Care. 2011;34(6):1323–8. https://doi.org/10.2337/dc10-2109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzalez-Sanchez JL, Seclen S, Villena A, Gonzalez-Villalpando C, Williams K, Haffner SM. Geographic variations of the international diabetes federation and the National Cholesterol Education Program – Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care. 2006;29(3):685–91.

    Article  PubMed  Google Scholar 

  51. Lucove JC, Kaufman JS, James SA. Association between adult and childhood socioeconomic status and prevalence of the metabolic syndrome in African Americans: the Pitt County study. Am J Public Health. 2007;97(2):234–6. https://doi.org/10.2105/AJPH.2006.087429.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med. 2004;21(4):383–7. https://doi.org/10.1111/j.1464-5491.2004.01115.x.

    Article  CAS  PubMed  Google Scholar 

  53. Mattsson N, Ronnemaa T, Juonala M, Viikari JS, Raitakari OT. The prevalence of the metabolic syndrome in young adults. The cardiovascular risk in young Finns study. J Intern Med. 2007;261(2):159–69. https://doi.org/10.1111/j.1365-2796.2006.01752.x.

    Article  CAS  PubMed  Google Scholar 

  54. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34 (1):216–219:216. https://doi.org/10.2337/dc10-0879.

    Article  Google Scholar 

  55. Nestel P, Lyu R, Low LP, Sheu WH, Nitiyanant W, Saito I, Tan CE. Metabolic syndrome: recent prevalence in east and southeast Asian populations. Asia Pac J Clin Nutr. 2007;16(2):362–7.

    PubMed  Google Scholar 

  56. Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, Tounouga DN, Tianyi FL, Foka AJ, Ndoadoumgue AL, Bigna JJ. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health. 2022;6(3):158–70. https://doi.org/10.1016/S2352-4642(21)00374-6. Epub 2022 Jan 17. PMID: 35051409

    Article  PubMed  Google Scholar 

  57. Onat A, Hergenc G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metab Clin Exp. 2011;60(4):499–512. https://doi.org/10.1016/j.metabol.2010.04.018.

    Article  CAS  PubMed  Google Scholar 

  58. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, Yazici M, Keles I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19(10):1055–62. https://doi.org/10.1016/j.amjhyper.2006.02.014.

    Article  CAS  PubMed  Google Scholar 

  59. Onat A, Can G, Hergenc G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes. 2007;31(7):1119–25. https://doi.org/10.1038/sj.ijo.0803552.

    Article  CAS  Google Scholar 

  60. Onat A, Ozhan H, Erbilen E, Albayrak S, Kucukdurmaz Z, Can G, Keles I, Hergenc G. Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol. 2009;135(2):211–7. https://doi.org/10.1016/j.ijcard.2008.03.054.

    Article  PubMed  Google Scholar 

  61. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research G. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med. 2005;142(8):611–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Park MJ, Yun KE, Lee GE, Cho HJ, Park HS. A cross-sectional study of socioeconomic status and the metabolic syndrome in Korean adults. Ann Epidemiol. 2007;17(4):320–6. https://doi.org/10.1016/j.annepidem.2006.10.007.

    Article  PubMed  Google Scholar 

  63. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 Suppl 1):S10–6. https://doi.org/10.1016/j.amjmed.2006.01.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA. 2003;290(17):2277–83. https://doi.org/10.1001/jama.290.17.2277.

    Article  CAS  PubMed  Google Scholar 

  65. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.

    Article  CAS  PubMed  Google Scholar 

  66. Rubin D, Claas S, Pfeuffer M, Nothnagel M, Foelsch UR, Schrezenmeir J. S-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal. Lipids Health Dis. 2008;7:32. https://doi.org/10.1186/1476-511X-7-32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep. 2002;4(6):494–500.

    Article  PubMed  Google Scholar 

  68. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24(4):621–6. https://doi.org/10.1097/01.hjh.0000217840.26971.b6.

    Article  CAS  PubMed  Google Scholar 

  69. Silventoinen K, Pankow J, Jousilahti P, Hu G, Tuomilehto J. Educational inequalities in the metabolic syndrome and coronary heart disease among middle-aged men and women. Int J Epidemiol. 2005;34(2):327–34. https://doi.org/10.1093/ije/dyi007.

    Article  PubMed  Google Scholar 

  70. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral M, Lorcaserin for O, Obesity Management Study G. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56. https://doi.org/10.1056/NEJMoa0909809.

    Article  CAS  PubMed  Google Scholar 

  71. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340–9. https://doi.org/10.1345/aph.1R501.

    Article  CAS  PubMed  Google Scholar 

  72. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–89. https://doi.org/10.1172/JCI129186. PMID: 31524630

    Article  PubMed  PubMed Central  Google Scholar 

  73. Stefan N, Schulze MB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol. 2023;11(6):426–40. https://doi.org/10.1016/S2213-8587(23)00086-4. Epub 2023 May 5.PMID: 37156256

    Article  CAS  PubMed  Google Scholar 

  74. Sun SS, Liang R, Huang TT, Daniels SR, Arslanian S, Liu K, Grave GD, Siervogel RM. Childhood obesity predicts adult metabolic syndrome: the Fels longitudinal study. J Pediatr. 2008;152(2):191–200. https://doi.org/10.1016/j.jpeds.2007.07.055.

    Article  CAS  PubMed  Google Scholar 

  75. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. https://doi.org/10.1136/bmj.d7771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Wamala SP, Lynch J, Horsten M, Mittleman MA, Schenck-Gustafsson K, Orth-Gomer K. Education and the metabolic syndrome in women. Diabetes Care. 1999;22(12):1999–2003.

    Article  CAS  PubMed  Google Scholar 

  77. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2005;25(11):2376–80. https://doi.org/10.1161/01.ATV.0000187465.55507.85.

    Article  CAS  PubMed  Google Scholar 

  78. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350(23):2362–74. https://doi.org/10.1056/NEJMoa031049.

    Article  CAS  PubMed  Google Scholar 

  79. Weng X, Liu Y, Ma J, Wang W, Yang G, Caballero B. An urban–rural comparison of the prevalence of the metabolic syndrome in eastern China. Public Health Nutr. 2007;10(2):131–6. https://doi.org/10.1017/S1368980007226023.

    Article  PubMed  Google Scholar 

  80. Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract. 2007;77(2):251–7. https://doi.org/10.1016/j.diabres.2006.12.001.

    Article  PubMed  Google Scholar 

  81. Zreikat HH, Harpe SE, Slattum PW, Mays DP, Essah PA, Cheang KI. Effect of renin-angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome. Metab Clin Exp. 2014;63(3):392–9. https://doi.org/10.1016/j.metabol.2013.11.006.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by National Institutes of Health grants R01DK135751 and RF1 AG059621, American Heart Association Cardiometabolic and Type 2 Diabetes SRFN, and American Heart Association Obesity SFRN.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Rexford S. Ahima

Authors
  1. Rexford S. Ahima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rexford S. Ahima .

Editor information

Editors and Affiliations

  1. Perelman School of Medicine, University of Pennsylvania, Pennsylania, PA, USA

    Rexford S. Ahima

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ahima, R.S. (2023). Overview of Metabolic Syndrome. In: Ahima, R.S. (eds) Metabolic Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-12125-3_1-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12125-3_1-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12125-3

  • Online ISBN: 978-3-319-12125-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Overview of Metabolic Syndrome
    Published:
    01 August 2023

    DOI: https://doi.org/10.1007/978-3-319-12125-3_1-2

  2. Original

    Overview of Metabolic Syndrome
    Published:
    26 June 2015

    DOI: https://doi.org/10.1007/978-3-319-12125-3_1-1

Search

Navigation